| 发明名称 |
Compositions and methods |
| 摘要 |
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. |
| 申请公布号 |
US9480735(B2) |
申请公布日期 |
2016.11.01 |
| 申请号 |
US201414283727 |
申请日期 |
2014.05.21 |
| 申请人 |
Glaxo Group Limited;GlaxoSmithKline Biologicals, SA |
发明人 |
Mettens Pascal;Brown James;Murphy Dennis |
| 分类号 |
A61K39/00;A61K39/02;A61K39/04;C07K14/35;C12N9/88;C12N9/90;A61K38/00 |
主分类号 |
A61K39/00 |
| 代理机构 |
|
代理人 |
Kron Eric J. |
| 主权项 |
1. A sterile pharmaceutical composition comprising a polypeptide which comprises:
(i) an Rv2386c protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 6; or (ii) an Rv2386c protein comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 6; and a pharmaceutically acceptable carrier or excipient. |
| 地址 |
Brentford, Middlesex GB |
